MX2019006598A - Celulas asesinas naturales modificadas geneticamente y sus usos. - Google Patents

Celulas asesinas naturales modificadas geneticamente y sus usos.

Info

Publication number
MX2019006598A
MX2019006598A MX2019006598A MX2019006598A MX2019006598A MX 2019006598 A MX2019006598 A MX 2019006598A MX 2019006598 A MX2019006598 A MX 2019006598A MX 2019006598 A MX2019006598 A MX 2019006598A MX 2019006598 A MX2019006598 A MX 2019006598A
Authority
MX
Mexico
Prior art keywords
natural killer
genetically modified
killer cells
modified natural
cells
Prior art date
Application number
MX2019006598A
Other languages
English (en)
Spanish (es)
Inventor
Eamon Peter O''dwyer Michael
Original Assignee
Onkimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60937693&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019006598(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Onkimmune Ltd filed Critical Onkimmune Ltd
Publication of MX2019006598A publication Critical patent/MX2019006598A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001126—CD38 not IgG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/36—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4222—CD38 not IgG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2019006598A 2016-12-09 2017-12-11 Celulas asesinas naturales modificadas geneticamente y sus usos. MX2019006598A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662432302P 2016-12-09 2016-12-09
PCT/EP2017/082292 WO2018104562A1 (en) 2016-12-09 2017-12-11 Engineered natural killer cells and uses thereof

Publications (1)

Publication Number Publication Date
MX2019006598A true MX2019006598A (es) 2019-10-15

Family

ID=60937693

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006598A MX2019006598A (es) 2016-12-09 2017-12-11 Celulas asesinas naturales modificadas geneticamente y sus usos.

Country Status (12)

Country Link
US (2) US10799536B2 (enExample)
EP (4) EP3895712B1 (enExample)
JP (2) JP7228900B2 (enExample)
KR (1) KR20190114966A (enExample)
CN (2) CN117305250A (enExample)
AU (1) AU2017371517B2 (enExample)
BR (1) BR112019011450A2 (enExample)
CA (1) CA3045386A1 (enExample)
DK (2) DK3454871T3 (enExample)
ES (3) ES2746856T3 (enExample)
MX (1) MX2019006598A (enExample)
WO (1) WO2018104562A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10906951B2 (en) * 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
JP7373991B2 (ja) * 2016-07-15 2023-11-06 ビラクタ セラピューティクス，インク． 免疫療法で使用するためのヒストン脱アセチル化酵素阻害剤
US10799536B2 (en) 2016-12-09 2020-10-13 Onk Therapeutics Limited Method of treating multiple myeloma using natural killer cells expressing a chimeric antigen receptor for CD38
AU2019271366B2 (en) * 2018-05-16 2026-02-26 Research Institute At Nationwide Children's Hospital Generation of knock-out primary and expanded human NK cells using Cas9 ribonucleoproteins
JP7241161B2 (ja) * 2018-08-01 2023-03-16 イミュニティーバイオ、インコーポレイテッド 細胞免疫療法の安定した遺伝子改変のための、ホーミング受容体又はサイトカインとキメラ抗原受容体とを含むクアドリシストロニックシステム
EP3843750A4 (en) * 2018-08-29 2022-05-25 Academia Sinica COMBINATION OF NATURAL KILLER CELLS AND CYCLOPHOSPHAMIDE COMPOUNDS FOR THE TREATMENT OF CANCER
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020189942A1 (ko) * 2019-03-15 2020-09-24 한국과학기술연구원 암 상살 능력이 향상된 면역세포
KR102292657B1 (ko) 2019-03-15 2021-08-24 한국과학기술연구원 암 상살 능력이 향상된 면역세포
CN109970869A (zh) * 2019-04-12 2019-07-05 南京卡提医学科技有限公司 一种靶向人trail死亡受体的嵌合受体配体及其应用
US20220193138A1 (en) * 2019-04-25 2022-06-23 Purdue Research Foundation Engineered natural killer cells redirected toward purinergic signaling, constructs thereof, and methods for using the same
KR20220093337A (ko) * 2019-10-31 2022-07-05 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 Cd38 녹아웃 일차 및 확장된 인간 nk 세포의 생성
WO2021146521A1 (en) * 2020-01-16 2021-07-22 Acepodia Biotechnologies Ltd. A novel cd16+ natural killer cell and a method of culturing cd16+ natural killer cell
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
WO2021209625A1 (en) * 2020-04-17 2021-10-21 Onk Therapeutics Limited High potency natural killer cells
EP4205761A4 (en) * 2020-08-27 2024-05-29 Cellid Co., Ltd NOVEL RECOMBINANT CORONAVIRUS SPIKE PROTEIN, POLYNUCLEOTIDE ENCODING THE SAME, VECTOR COMPRISING THE POLYNUCLEOTIDE, AND VACCINE FOR THE PREVENTION OR TREATMENT OF CORONAVIRUS INFECTION, COMPRISING THE VECTOR
EP4204546A1 (en) 2020-08-31 2023-07-05 City of Hope Novel cell lines, methods of producing natural killer cells and uses thereof
CN114426583B (zh) * 2020-10-29 2023-10-10 中国科学技术大学 用于急性髓系白血病的细胞疗法的嵌合抗原受体
KR20220091426A (ko) * 2020-12-23 2022-06-30 주식회사 휴먼셀바이오 혈액 유래 물질 및 면역세포를 포함하는 암 또는 면역질환의 예방 또는 치료용 약학조성물
JP2024522756A (ja) 2021-06-18 2024-06-21 オーエヌケイ セラピューティクス リミテッド ダブルノックアウトナチュラルキラー細胞
US20240316102A1 (en) 2021-07-01 2024-09-26 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and related methods
WO2023010038A1 (en) * 2021-07-29 2023-02-02 Seattle Children's Hospital (dba Seattle Children's Research Institute) Synthetic nucleic acid elements for enhancing car t cell efficacy
US20250145693A1 (en) * 2021-09-18 2025-05-08 Sunnybay Biotech, Inc. Herv-k antibody, cell, vaccine, and drug therapeutics
WO2023102201A2 (en) * 2021-12-03 2023-06-08 University Of Utah Research Foundation High selective cd229 antigen binding domains and methods of use
CA3259982A1 (en) 2022-06-30 2024-01-04 Indapta Therapeutics, Inc. COMBINATION OF MODIFIED NATURAL KILLER (NK) CELLS AND ANTIBODY THERAPY AND ASSOCIATED METHODS
EP4353741A1 (en) 2022-10-14 2024-04-17 ONK Therapeutics Limited Double knockout natural killer cells
EP4615471A1 (en) 2022-11-10 2025-09-17 ONK Therapeutics Limited Combined therapies using immunomodulating drugs
WO2024238387A1 (en) * 2023-05-12 2024-11-21 Nkmax Co., Ltd. Method of treating alzheimer's disease with expanded natural killer cells
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells
WO2025073908A1 (en) 2023-10-05 2025-04-10 Onk Therapeutics Limited Optimised il-15 constructs
WO2025146467A1 (en) 2024-01-04 2025-07-10 Onk Therapeutics Limited Targeted il-15 construct delivery
KR20250118299A (ko) 2024-01-29 2025-08-06 인하대학교 산학협력단 전기자극 시스템을 활용한 자연살해세포의 암세포 살상 능력 증진 방법
WO2025184169A1 (en) * 2024-02-26 2025-09-04 The Regents Of The University Of California Oleate-mediated enhancement of human natural killer cell function
WO2025239292A1 (ja) * 2024-05-15 2025-11-20 株式会社Cured 改変ナチュラルキラー細胞株

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2516128A1 (en) * 2003-02-14 2004-09-02 Sagres Discovery, Inc. Therapeutic targets in cancer
EP3312196B1 (en) 2005-03-23 2019-07-17 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
NZ576122A (en) 2006-09-26 2012-09-28 Genmab As Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
JP2010507366A (ja) 2006-10-19 2010-03-11 メルク アンド カンパニー インコーポレイテッド インターロイキン−１３受容体α１の抗体アンタゴニスト
GB0724532D0 (en) 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
EP3613774A1 (en) * 2010-06-09 2020-02-26 Genmab A/S Antibodies against human cd38
EP2964753B1 (en) 2013-03-07 2018-04-25 Baylor College of Medicine Targeting cd138 in cancer
US10836998B2 (en) * 2014-02-14 2020-11-17 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
JP6772063B2 (ja) * 2014-02-14 2020-10-21 ベリカム ファーマシューティカルズ， インコーポレイテッド 誘導可能なキメラポリペプチドを使用して細胞を活性化するための方法
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
JP2017513818A (ja) 2014-03-15 2017-06-01 ノバルティス アーゲー キメラ抗原受容体を使用する癌の処置
EP3237436B1 (en) 2014-12-24 2019-05-01 Aadigen, Llc Peptides and nanoparticles for intracellular delivery of molecules
HK1246180A1 (zh) 2014-12-31 2018-09-07 Celgene Corporation 使用自然杀伤细胞治疗血液病症、实体瘤或感染性疾病的方法
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
CN108603170A (zh) 2015-06-12 2018-09-28 莱蒂恩技术公司 用工程改造的t细胞治疗癌症的方法
JP6961497B2 (ja) 2015-06-25 2021-11-05 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
EP3971284B1 (en) 2015-07-29 2023-11-08 ONK Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
US10906951B2 (en) 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
WO2018104554A1 (en) 2016-12-09 2018-06-14 Onkimmune Limited Improved nk-based cell therapy
US10799536B2 (en) * 2016-12-09 2020-10-13 Onk Therapeutics Limited Method of treating multiple myeloma using natural killer cells expressing a chimeric antigen receptor for CD38
US20190321402A1 (en) 2018-04-19 2019-10-24 Onkimmune Limited Nk cells for use with anitbodies in cancer therapy

Also Published As

Publication number Publication date
JP7228900B2 (ja) 2023-02-27
RU2019121509A3 (enExample) 2021-03-30
CA3045386A1 (en) 2018-06-14
ES2746856T3 (es) 2020-03-09
KR20190114966A (ko) 2019-10-10
ES2926397T3 (es) 2022-10-26
EP3895712B1 (en) 2022-06-22
US12534536B2 (en) 2026-01-27
AU2017371517A1 (en) 2019-07-04
EP4104841A1 (en) 2022-12-21
AU2017371517B2 (en) 2023-01-05
US10799536B2 (en) 2020-10-13
BR112019011450A2 (pt) 2019-10-15
CN117305250A (zh) 2023-12-29
RU2019121509A (ru) 2021-01-11
DK3581190T3 (da) 2021-06-07
JP2023052980A (ja) 2023-04-12
EP3581190B1 (en) 2021-03-10
DK3454871T3 (da) 2019-09-16
EP3581190A1 (en) 2019-12-18
WO2018104562A1 (en) 2018-06-14
EP3454871B1 (en) 2019-06-26
CN110248669A (zh) 2019-09-17
EP3454871A1 (en) 2019-03-20
EP3895712A1 (en) 2021-10-20
US20180161371A1 (en) 2018-06-14
US20210046118A1 (en) 2021-02-18
CN110248669B (zh) 2023-09-08
JP2020503891A (ja) 2020-02-06
ES2875005T3 (es) 2021-11-08

Similar Documents

Publication Publication Date Title
MX2019006598A (es) Celulas asesinas naturales modificadas geneticamente y sus usos.
CO2020010956A2 (es) Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
MX2020001996A (es) Moleculas anti-cd137 y uso de estas.
CL2019000061A1 (es) Anticuerpo para anti-claudin 18a2 y su utilización.
MX2017002205A (es) Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
CL2020002446A1 (es) Anticuerpos contra mica y/o micb y sus usos
CL2019000326A1 (es) Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos
CL2018003153A1 (es) Moléculas de anticuerpo para el tratamiento del cáncer.
MX2019009468A (es) Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer.
AR113881A1 (es) Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia
MX2020007338A (es) Composiciones y métodos para el direccionamiento a tipos de cáncer que expresan clec12a.
MX385585B (es) Anticuerpos anti-c10orf54 y usos de los mismos.
MX2021013837A (es) Enfoque de inmunoterapias de combinacion para el tratamiento del cancer.
MX2017001008A (es) Tratamiento de cancer utilizando un receptor quimerico de antigeno cd33.
AR105433A1 (es) Métodos para mejorar la eficacia y expansión de las células inmunes
ECSP17031725A (es) Receptores quiméricos de anitígeno anti-clon y métodos de uso
UY36862A (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso
MX2020004935A (es) Terapias con celulas inmunitarias multifuncionales.
MX2017008875A (es) Anticuerpos biespecificos contra cd3 y cd20.
CO2017000506A2 (es) Receptor quimérico de antígeno cll-1
AR104664A1 (es) Conjugados de fármacos con anticuerpos contra la cadherina 6 (anti-cdh6)
GT201500248A (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
MX2017002459A (es) Anticuerpos y receptores de antigeno quimericos especificos para cd19.
MX2017001011A (es) Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.